To explore the function of the C5orf46 gene in human pan-cancer, particularly in kidney renal clear cell carcinoma (KIRC), and its potential clinical applications in cancer prognosis and treatment.
Key Findings:
C5orf46 is upregulated in various cancers, with KIRC showing the most significant expression difference, indicating its potential as a therapeutic target.
Increased C5orf46 expression correlates with worse overall survival and shorter recurrence-free survival, highlighting its prognostic value.
C5orf46 expression is influenced by DNA methylation, suggesting epigenetic regulation.
C5orf46 is associated with angiogenesis, immune infiltration, ECM degradation, and cancer EMT, indicating its role in tumor progression.
C5orf46 correlates with sensitivity to certain chemotherapy drugs, suggesting its potential as a predictive biomarker.
Interpretation:
C5orf46 may function as an oncogene across multiple cancers, particularly influencing tumor microenvironment dynamics and patient prognosis, warranting further investigation into its therapeutic potential.
Limitations:
The study relies on data from TCGA and local hospital samples, which may limit generalizability and introduce selection bias.
Further validation in larger, diverse cohorts is needed to confirm findings and assess the clinical applicability of C5orf46.
Conclusion:
C5orf46 has potential as a prognostic biomarker in cancer, particularly in KIRC, and is associated with critical cancer traits, suggesting its role in guiding treatment decisions.
